A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease by Kau, Punit et al.
RESEARCH ARTICLE Open Access
A mouse model for triple-negative breast cancer
tumor-initiating cells (TNBC-TICs) exhibits similar
aggressive phenotype to the human disease
Punit Kaur
1, Ganachari M Nagaraja
1, Hongying Zheng
1, Dawit Gizachew
2, Moses Galukande
3, Sunil Krishnan
4 and
Alexzander Asea
1,5*
Abstract
Background: Triple-negative breast cancer (TNBC) exhibit characteristics quite distinct from other kinds of breast
cancer, presenting as an aggressive disease–recurring and metastasizing more often than other kinds of breast
cancer, without tumor-specific treatment options and accounts for 15% of all types of breast cancer with higher
percentages in premenopausal African-American and Hispanic women. The reason for this aggressive phenotype is
currently the focus of intensive research. However, progress is hampered by the lack of suitable TNBC cell model
systems.
Methods: To understand the mechanistic basis for the aggressiveness of TNBC, we produced a stable TNBC cell
line by sorting for 4T1 cells that do not express the estrogen receptor (ER), progesterone receptor (PgR) or the
gene for human epidermal growth factor receptor 2 (HER2). As a control, we produced a stable triple-positive
breast cancer (TPBC) cell line by transfecting 4T1 cells with rat HER2, ER and PgR genes and sorted for cells with
high expression of ER and PgR by flow cytometry and high expression of the HER2 gene by Western blot analysis.
Results: We isolated tumor-initiating cells (TICs) by sorting for CD24
+/CD44
high/ALDH1
+ cells from TNBC (TNBC-
TICs) and TPBC (TPBC-TICs) stable cell lines. Limiting dilution transplantation experiments revealed that CD24
+/CD44
high/ALDH1
+ cells derived from TNBC (TNBC-TICs) and TPBC (TPBC-TICs) were significantly more effective at
repopulating the mammary glands of naïve female BALB/c mice than CD24
-/CD44
-/ALDH1
- cells. Implantation of
the TNBC-TICs resulted in significantly larger tumors, which metastasized to the lungs to a significantly greater
extent than TNBC, TPBC-TICs, TPBC or parental 4T1 cells. We further demonstrated that the increased
aggressiveness of TNBC-TICs correlates with the presence of high levels of mouse twenty-five kDa heat shock
protein (Hsp25/mouse HspB1) and seventy-two kDa heat shock protein (Hsp72/HspA1A).
Conclusions: Taken together, we have developed a TNBC-TICs model system based on the 4T1 cells which is a
very useful metastasis model with the advantage of being able to be transplanted into immune competent
recipients. Our data demonstrates that the TNBC-TICs model system could be a useful tool for studies on the
pathogenesis and therapeutic treatment for TNBC.
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Triple-negative breast cancer (TNBC) is characterized
by a lack of receptor expression of estrogen receptor
(ER) and progesterone receptor (PgR) and lack of gene
expression for human epidermal growth factor receptor
2 (HER2) [1,2]. Chemotherapy remains the only possible
therapeutic option in the adjuvant or metastatic setting
in the TNBC. Importantly, the prognostic effect of
TNBC is independent of poor grade, nodal status,
tumor size and treatment [3]. The aggressiveness of
TNBC is further indicated by the fact that: (i) the peak
risk of recurrence occurs within the first 3 years after
initial treatment of the disease with the majority of
deaths occurring in the first 5 years [4] and (ii) after
diagnosis of metastatic disease, a significantly shorter
survival is observed in TNBC [4]. Conversely, the risk
for late recurrences (i.e. beyond 5 years of diagnosis) is
decreased by 50% compared with HER2-positive disease
[5]. More than 90% of TNBC exhibit an invasive ductal
histology and high histological grade, present with high
mitotic index and carry central necrotic zones and push-
ing borders as well as a conspicuous lymphocytic
infiltrate.
TNBC are typically observed in young African-American
women, Hispanic women and Caucasian women who
carry a mutation in the breast cancer 1 (BRCA1) early
onset gene [6]. While some TNBC respond to chemother-
apy, subsets of TNBC are chemotherapy-resistant and
highly metastatic carrying with it an extremely poor prog-
nosis [6]. The molecular mechanism, which governs the
aggressive behavior of this subset of TNBC, is a matter of
intense speculation, particularly since TNBC frequently
express markers of epithelial mesenchymal transition
(EMT). EMT is a normal developmental process in which
cells of epithelial origin lose epithelial characteristics and
polarity and acquire a mesenchymal phenotype associated
with increased migratory behavior [7,8].
Self-renewing cancer cells are reported to be the only
cell types within a tumor with an unlimited ability to
initiate tumor growth and are therefore known as
tumor-initiating cells (TICs), cancer stem cells or
tumor-propagating cells [9-11]. The majority of carci-
noma cells express a CD44
low/CD24
high phenotype; how-
ever, a small subpopulation of carcinoma cells present
within human breast cancers that exhibit a CD44
high/
CD24
low a n t i g e n i cp h e n o t y p ea r eh i g h l ye n r i c h e df o r
TICs [12]. TNBC have been reported to have a higher
percentage of CD44
high/CD24
low expressing cells than
other breast cancer subtypes [13].
The mouse twenty-five kDa heat shock protein (Hsp25/
mouse HspB1) belongs to the family of small HSP and is
the murine homologue of human twenty-seven kDa heat
shock protein (Hsp27/human HspB1) which operates
through ATP-independent mechanisms [14,15]. Elevated
human HspB1 levels have been found in various tumors,
including breast, prostate, gastric, uterine, ovarian, head
and neck, and tumors arising from the nervous system
and urinary system. Elevated levels of human HspB1 in
ER-a positive benign neoplasia have been shown to pro-
mote the progression to more malignant phenotypes
[16], increased anchorage independent tumor growth
[17], increased resistance to chemotherapeutic drugs
(including cisplatin and doxorubicin) and increased
metastatic potential in vitro [18-20]. Furthermore, ele-
v a t e dh u m a nH s p B 1e x p r e s s i o ni nt u m o r sc o r r e l a t e d
with shorter disease-free survival and recurrence in
node-negative breast cancer [21,22], whereas its induc-
tion following chemotherapy also predicted poor prog-
nosis and shorter disease-free survival [23].
Surface bound/expressed and total Hsp25 (mouse
HspB1) and Hsp72 (HspA1A) on 4T1 murine breast ade-
nocarcinoma tumors suggest that tumor development
and metastatic spread favors cells that express high levels
of mouse HspB1 on their plasma surface. However,
tumors that express Hsp72/HspA1A on their plasma sur-
face are sensitive to anti-tumor effector cells, which indi-
cate increased surface expression of Hsp72/HspA1A on
tumors and down regulation of human HspB1 expression
could inhibit tumor growth and eliminate metastasis
[24,25]. Enhanced expression of intracellular Hsp72/
HspA1A has shown to be anti-inflammatory [26], anti-
apoptotic [18], induce cell cycle arrest [27] and protect
cells from stressful stimuli [28]. In contrast, enhanced
extracellular expression of Hsp72/HspA1A either on the
surface of tumors or in the extracellular milieu either
enhances natural killer (NK) cell-mediated lysis [29] or
upregulates antigen presenting cells (APC)-mediated
acute phase responses [30-33], respectively. A study in
which the mouse hspb1 gene has been silenced using
interference ribonucleic acid (RNAi) technology suggests
that mouse HspB1 has a profound effect on tumor prolif-
eration and migration [24,25].
In this study, we constructed TNBC and TPBC by the
stable transfection of parental 4T1 cells with the rat
HER2, ER and PgR genes and sorted for cells with high
expression of HER2, ER and PgR. We further produced
TNBC-TICs and TPBC-TICs by sorting CD24
+/CD44
high/aldehyde dehydrogenase 1 (ALDH1)
+ expres-
sing cells from TNBC and TPBC. Functional analysis
demonstrated that TNBC-TICs exhibits a more aggres-
sive phenotype than TNBC, TPBC, TPBC-TICs or par-
ental 4T1 cells. Taken together, our studies suggest that
these cells could be important preclinical model to char-
acterize and effectively target cancer stem cells or TICs,
and to further our understanding of the aggressive nat-
ure of TNBC found in humans.
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Cells and culture conditions
4 T 1 ,ah i g h l ym e t a s t a t i cb r e a s tc a n c e rc e l ll i n ed e r i v e d
from a spontaneously arising BALB/c mammary tumor
were purchased from American Type Culture Collection
( A T C C ;R o c k v i l l e ,M D ) .4 T 1cells were maintained in
monolayer cultures in Dulbecco’s modified Eagle’sm e d -
ium (DMEM) (Sigma Chemical, St. Louis, MO) supple-
mented with 10% fetal bovine serum (FBS). Cells were
maintained at 37°C humidified atmosphere with 5% CO2.
Animals and tumor challenge
Female BALB/c (H2
d) wild type mice (6-8 weeks old)
were purchased from Charles River Laboratories (Wil-
mington, MA) and housed under pathogen-free condi-
tions in laminar flow isolation units in the Scott &
White Hospital vivarium under alternate dark and light
cycles, and maintained on food and water ad libitum.
Female BALB/c (6-8 weeks old) were lightly anesthe-
tized and the fur was shaved over the lateral thorax and
a 5-mm-long incision was made to reveal mammary fat
pad number 2. A 0.1-ml sample containing 10
4 tumors
was injected into the mammary fat pad and the incision
was closed with a wound clip. Tumor volume was mea-
sured once a week using an electronic caliper. The
tumor volume was estimated using the formula of an
ellipsoid (length × width × height × 0.5236). All animals
were treated humanely and in accordance with the
guidelines of the Committee on the Care and Use of
Laboratory Animals of the Institute of Animal
Resources, National Research Council and Institutional
Animal Care and Use Committee (IACUC) of Scott &
White Hospital. For each group 5 mice were used for
statistical significance.
Establishment of stable cell line
For the construction of HER
+/ER
+/PgR
+ 4T1 cells (TPBC)
the 550 bp rat human epidermal growth factor receptor 2
(HER2) (extracellular domain containing the herceptin
domain) upstream primer (5’-GTCGAAGCTTATG-
GAGCTGGCGGCCTGG-3’) and downstream primer (5’-
GACTGAATTCTTAGTTGATGGGGCACGG-3’), and
the 311 bp rat estrogen receptor (ER) upstream primer
(5’-TGACTCTGCAGCAACAGCAT-3’) and downstream
primer (5’-GAGTTCTCAGATGGTGTTGG-3’)a n dt h e
460 bp rat progesterone receptor (PgR) upstream primer
(5’-AACTGGTTCCGCCACTCAT-3’)a n dd o w n s t r e a m
primer (5’-AACTGGTTCCGCCACTCAT-3’)w e r eu s e d
and cloned into a pcDNA6.2/EmGFP construct according
to the manufactures’ instructions (Invitrogen). For stable
transfection pcDNA6.2/EmGFP construct was linearized
before transfection into 4T1 cells using Lipofectamine™
2000 Reagent (Invitrogen). Similarly, for the construction
of HER
-/ER
-/PgR
- 4T1 cells (TNBC), the pcDNA6.2/
EmGFP vector alone was used. Forty-eight hours after
transfection, cells were split and growth media containing
DMEM supplemented with 10% FBS and 10 μg/ml Blasti-
cidin (Invitrogen) was added. After 4 days Blasticidin-resis-
tant colonies were identified and further propagated. Cells
stably transfected with enhanced green fluorescent protein
(eGFP) were further enriched for eGFP-positive popula-
tions by sorting using a BD FACSAria flow cytometer (BD
Biosciences) equipped with a 488 nm argon laser. The
emission filter for eGFP was set at 515-545 nm. The pre-
sence of HER2, PgR and ER in TPBC was confirmed by
Western blot analysis and PCR. Pure TNBC cells were
obtained after Flow Cytometry sorting for ER
-/PgR
- 4T1
cells.
Limiting dilution transplantation assay
After FACS sorting for 4T1wt, TNBC, TNBC-TICs,
TPBC, TPBC-TICs expressing high levels of enhanced
green fluorescence protein (eGFP), cells were washed
once with ice-cold PBS and mixed in DMEM supple-
mented with 25% Matrigel (BD Biosciences). Female
BALB/c (6-8 weeks old) were lightly anesthetized and
the fur was shaved over the lateral thorax and a 5-mm-
long incision was made to reveal mammary fat pad
number 2. A 0.1-ml sample containing various concen-
trations of eGFP-bearing cells (500, 100, 50, 25 and 10)
was injected into the mammary fat pad and the incision
was closed with a wound clip. Confidence interval (95%)
for repopulating mammary cell frequency were calcu-
lated using ELDA, a software application for limiting
dilution analysis (LDA) as previously described [34]. All
animals were treated humanely and in accordance with
the guidelines of the Committee on the Care and Use of
Laboratory Animals of the Institute of Animal
Resources, National Research Council and Institutional
Animal Care and Use Committee (IACUC) of Scott &
White Hospital. For each group 5 mice were used for
statistical significance.
Live animal imaging
Live animal imaging was achieved by measuring the
spectral fluorescence images captured using the Maes-
tro™ in vivo imaging system (CRI, Woburn, MA). An
excitation band pass filter from 445 to 490 nm and an
emission filter over 515 nm were used. The tunable fil-
ter was automatically spaced in 10 nm increments from
500 to 720 nm while the camera captured fluorescence
images at each wavelength with constant exposure. RGB
(red-green-blue) color fluorescence images were synthe-
sized from the spectral cube by mapping the spectral
data into those color channels. All the fluorescence
images obtained as RGB images were derived from the
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segregate skin and hair auto fluorescence and to mea-
sure the true eGFP signal.
Clonogenicity assay
The ability of tumor cells to metastasize to distant
organs was assessed using the clonogenicity assay as
previously described [26,35]. Briefly, mice were sacrificed
and lung tissue was aseptically removed, minced with
trypsin, seeded in triplicate at 1,000 cells/per 60 mm
3
petri-dish and incubated at 37°C in a 5% CO2 air atmo-
sphere. Ten to twelve days later, the plates were washed
twice with PBS and colonies were stained with crystal
violet and counted. The colonizing efficiency was scored
and results were compared to those in vehicle-treated
cells.
Protein separation and western blot analysis
Following various treatment protocols cells were washed
once with complete medium, centrifuged and pellets
lysed with 100 μl of lysing buffer containing a cocktail
of protease inhibitors (antipain, bestain, chymostatin, E-
64, pepstatin, phosphoramidon, pefabloc, ethylenediami-
netetraacetic acid (EDTA), aprotinin; Complete Protease
Inhibitor Cocktail Tablets
®, Roche Diagnostics). Cells
were then incubated for 30 min on ice and sonicated
(Brandson 1510) for 15 min. The cell suspension was
p a s s e dt h r o u g ha2 6 - g a u g en e e d l ea n dp r o t e i nq u a n t i f i -
cation was performed using the Bradford method. Pro-
teins were separated in a 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) by care-
fully placing 30 μg of protein in each lane. Polyvinyli-
dene fluoride (PVDF) (Millipore) was used to transfer
the proteins and the membrane blocked with 5% skim
milk (in TBS 1% pH 7.4 and 0.01% Tween 20) and incu-
bated for 1 h at room temperature with appropriate pri-
mary antibodies; anti-Hsp72/HspA1A and anti-Hsp73/
HspA8 (StressGen Biotechnologies, BC, Canada), or b-
actin (Oncogene, San Diego, CA) with 1:1000 dilution.
Blots were incubated 50 min at room temperature with
0.5 μg of appropriate species matched anti-peroxidase
and the reaction was detected using the Luminol
reagent for chemiluminescence (Santa Cruz Biotechnol-
ogy). The intensity of the bands were analyzed by densi-
tometry with a video densitometer (Chemilmager™
5500; Alpha Innotech, San Leandro, CA) using the AAB
software (American Applied Biology).
Flow cytometry and cell sorting
For the isolation of TICs from TNBC and TPBC; 10
7
cells were stained with anti-CD24-FITC (1:100, BD
Transduction Labs), anti-CD44-PE (1:200, BD Transduc-
tion Labs) and anti-ALDH1-Alexa-Fluor-568 (1:100,
M o l e c u l a rP r o b e s )u n d e rp r e v i o u s l yo p t i m i z e d
conditions. Isotype controls (IgG) were used as negative
controls. CD24
+/CD44
high/ALDH1
+ and CD24
-/CD44
-/
ALDH1
- cells were sorted using a BD FACSort with a
Lysys II software program (BD Biosciences). Individual
cells were gated based on forward (FSC) and orthogonal
scatter (SSC). Cell debris was excluded by raising the
FSC-height photomultiplier (PMT) threshold. The PMT
for FITC (FL1-height), PE (FL2-height) and Alexa-Fluor
568 (FL-3-height) was set on a logarithmic scale. The
flow rate was adjusted to < 200 cells/second. Post sorted
cells were collected in cell culture medium containing
20% FBS and then washed and returned to 4T1 complete
medium; DMEM supplemented with 10% FBS and main-
tained at 37°C humidified atmosphere with 5% CO2.
Fluorescence microscopy
Standard fluorescence microscopy was performed using
an Olympus CKX41 microscope. A DP71 CCD camera
was used to capture phase contrast and eGFP fluores-
cence images with DP71 image acquisition interface
software (Olympus).
Statistical analysis
For comparisons between groups, Dunn multiple com-
parison tests and student t-test and one-way analysis of
variance (ANOVA) were used in this study (p values <
0.001 were considered significant).
Results
Development of mouse TNBC, TPBC and breast cancer
Tumor-Initiating Cells (TICs)
To understand the molecular characteristics of TNBC,
and determine the reason for its highly aggressive phe-
notype as compared to TPBC, we used the 4T1 breast
adenocarcinoma mouse cell line as a model system,
because tumor growth and metastatic spread of 4T1
cells very closely mimic human breast cancer and has
the advantage of being able to be transplanted into
immune competent recipients. To produce a population
of TNBC cells, we transfected parental 4T1 cells with
empty vector control and sorted for cells that do not
express HER2, ER or PgR (HER2
-/ER
-/PgR
-)u s i n gf l o w
cytometry and sorted to > 90% purity termed TNBC
(Figure 1A; middle panels). Western blot analysis
revealed that there was no significant increase in the
HER2 expression in TNBC, as compared to parental
4T1 cells and no expression of either ER or PgR (Figure
1B; lane 2). We then constructed a population of 4T1
breast cancer cells to mimic the TPBC phenotype in
humans, and that are phenotypically HER2
+/ER
+/PgR
+.
The rationale for creating a TPBC 4T1 cell line is to act
as a relevant control for the TNBC 4T1 cell line. This
was achieved by stable transfection of parental 4T1 cells
(Figure 1A; left panels) with the rat HER2, ER and PgR
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Page 4 of 12Figure 1 Transfection of rat HER2, ER and PgR genes into 4T1 cells produces a population of TNBC and TPBC. (A) Parental 4T1 cells
(10
6), TNBC (10
6), or TPBC (10
6) were placed on ice and stained with anti-ER-FITC (top panels) or anti-PgR-PE (bottom panels). The surface
intensity for these antibodies were analyzed by flow cytometry using a FACSort with a Lysys II software program (Becton & Dickinson). Individual
cells were gated based on forward (FSC) and orthogonal scatter (SSC). Cell debris was excluded by raising the FSC-height PMT threshold.
Histograms are mean relative counts and are a representative experiment of three independently performed experiments with similar results. (B)
Parental 4T1 cells (10
6) (lane 1), TNBC (10
6) (lane 2), or TPBC (10
6) (lane 3) were lysed and the amount of ErbB2 (HER2) was determined by
Western blot analysis using specific Mab as described in detail in the Materials and Methods section. b-actin was used as control for equal
loading. The intensity of the bands were analyzed by densitometry with a video densitometer (Chemilmager™ 5500; Alpha Innotech, San
Leandro, CA) using the AAB software (American Applied Biology). Data is a representative experiment from three independently performed
experiments with similar results.
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were then sorted for high expression of ER and PgR by
flow cytometry to > 90% purity and termed TPBC
(Figure 1A; right panels). Western blot analysis revealed
that the expression of HER2 (using anti-ErbB2 antibo-
dies) in TPBC increased approximately 500% above par-
ental 4T1 cell levels (Figure 1B; lane 3).
To isolate a population of breast cancer tumor-initiat-
ing cells (TICs), we stained the TNBC (HER2
-/ER
-/PgR
-)
and TPBC (HER2
+/ER
+/PgR
+) described above with
antibodies known to differentiate breast cancer stem
cells, including CD24 (a cell adhesion molecule), alde-
hyde dehydrogenase 1 (ALDH1; an enzyme that cata-
lyses the oxidation of aldehydes) and CD44 (a cell-
surface glycoprotein involved in cell-cell interactions,
cell adhesion and migration). We uncovered two pheno-
typically distinct populations in each group; a population
expressing CD24
+/ALDH1
+/CD44
high and another popu-
lation expressing CD24
-/ALDH1
-/CD44
low cells (data
not shown). Using flow cytometry sorting techniques,
we sorted for CD24
+/ALDH1
+/CD44
high cells to a >
90% purity (Figure 2).
Limiting dilution transplantation experiments were
then performed to validate that the CD24
+/ALDH1
+/CD44
high cells do in fact have greater tumor initiating
ability than CD24
+/ALDH1
-/CD44
low cells. Our results
demonstrated that CD24
+/ALDH1
+/CD44
high cell frac-
tion derived from TNBC and TPBC contain cells with a
significantly greater ability to repopulate the breast tis-
sue, as compared to CD24
+/ALDH1
-/CD44
low cells
derived from TNBC or TPBC (Table 1). The log-frac-
tion plot of the limiting dilution model was generated
using ELDA software for limiting dilution analysis
(LDA) after fitting the data from Table 1. We demon-
strated that the estimated 95% confidence intervals for
repopulating mammary cells frequencies for CD24
+/ALDH1
+/CD44
high cells derived from TNBC and
TPBC are 6.22 and 27.02, respectively, as compared to
3168.93 for CD24
+/ALDH1
-/CD44
low cells derived from
TNBC and TPBC (Table 2). The overall test for differ-
ences in stem cell frequencies between any of the
groups gave a Chi-Square score of 142 (p = 1.29 × 10
-
30). The likelihood ratio test, which is designed to test
whether the single-hit model is correct gave a Chi-
Square of 0.00411 (p = 0.949). The score test of hetero-
geneity, which is designed to test whether the different
cultures (assays) have the same active cell proportion
gave a Chi-Square of 0.728 (p = 0.394). The slopes for
CD24
+/ALDH1
+/CD44
high c e l l sd e r i v e df r o mT N B C
(green line) and TPBC (black lines), significantly differ
from CD24
+/ALDH1
-/CD44
low cells derived from either
TNBC (blue line) or TPBC (red line), which overlap due
to similar values (Figure 3). The estimated slope value is
1.02, since the value is greater than 1, this suggests a
multi-hit model in which two or more cells are synergis-
tically required to produce a positive response (Figure
3). We therefore termed the CD24
+/ALDH1
+/CD44
high
cells tumor-initiating cells (TICs). Thus, TICs derived
from TNBC were designated TNBC-TICs and TICs
derived from TPBC were designated TPBC-TICs.
Mouse TNBC-TICs proliferates faster and metastasizes to a
greater extent than TPBC-TICs or parental 4T1 wild type cells
We further demonstrated that CD24
+/ALDH1
+/CD44
high cells derived from TNBC (TNBC-TICs) pro-
liferated approximately 7-fold more than parental 4T1
cells, and that TPBC-TICs and TNBC proliferated 2-
fold and 3-fold more than the parental 4T1 cells, respec-
tively. We demonstrated that TPBC did not proliferated
significantly more than the parental 4T1 cells in vitro
(Figure 4). To determine the clonogenic growth poten-
tial and migratory properties of the newly developed
TICs, we implanted TICs into the breast pad of naïve
female BALB/c mice and demonstrated that TNBC-
TICs developed tumors approximately 4-fold larger than
parental 4T1 cells (Figure 5). We further demonstrated
that TPBC and TNBC produced tumors 1.5-fold and
2.5-fold larger than tumors developed by the parental
4T1 cells (Figure 5). To negate the possibility that
hematoxylin and eosin (H&E) staining of lung tissues
might inadvertently miss micro-metastasis, we used the
clonogenicity assay on the lungs of isolated 21 days post
tumor cell implantation and revealed that TNBC-TICs
and TNBC developed approximately 5-fold and 2-fold
more metastatic foci than the parental 4T1 cells, respec-
tively (data not shown). Interestingly, TPBC-TICs and
TPBC did not produce significantly more metastatic foci
than the parental 4T1 cells (Figure 6).
High levels of mouse HspB1 have been shown to be
associated with increased tumor growth and high meta-
static potential [24,25,36]. To determine if the increased
metastatic potential exhibited by TNBC-TICs is asso-
ciated with increased mouse HspB1expression, we
probed the cells with mouse HspB1 and Hsp72/HspA1A
after Western blot analysis and demonstrated that
TNBC-TICs express 876% higher levels of mouse HspB1
1,003% higher levels of Hsp72/HspA1A as compared to
parental 4T1 cells (Figure 7).
Discussion
This study was undertaken to address a critical need in
TNBC research; develop a model system which can be
used to elucidate the reason for the apparent highly
aggressive phenotype of triple-negative breast cancer
(TNBC). We have successfully developed four cell lines
derived from the parental 4T1 breast adenocarcinoma
mouse cell lines that can be used to study the pathogen-
esis and therapeutic treatment for TNBC.
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Page 6 of 12Figure 2 Selection of triple-negative breast cancer-cancer stem cells (TNBC-TICs). CD24, CD44 and ALDH1 antibodies were used to isolate
a population of breast cancer tumor-initiating cells (TICs) from TNBC. TNBC (10
6) were placed on ice and stained with anti-CD24-FITC (top
panels), anti-CD44-PE (middle panels) and anti-ALDH1 (bottom panels). Cells were sorted using a FACSort with a Lysys II software program
(Becton & Dickinson). Individual cells were gated based on forward (FSC) and orthogonal scatter (SSC). Cell debris was excluded by raising the
FSC-height PMT threshold. Histograms are mean relative counts and are a representative experiment of three independently performed
experiments with similar results.
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Page 7 of 12Table 1 TNBC-TICs exhibit a greater clonogenic growth
potential as compared to TNBC, TPBC-TICs, TPBC or
parental 4T1 cells
Cell type
1 Number
of cells
transplanted
Fraction
of mice
with tumors
2
TPBC-derived:
CD24
+/ALDH1
+/CD44
high 500 5/5
CD24
+/ALDH1
+/CD44
high 100 5/5
CD24
+/ALDH1
+/CD44
high 50 4/5
CD24
+/ALDH1
+/CD44
high 25 2/5
CD24
+/ALDH1
+/CD44
high 10 3/5
TPBC-derived:
CD24
+/ALDH1
-/CD44
low 500 1/5
CD24
+/ALDH1
-/CD44
low 100 0/5
CD24
+/ALDH1
-/CD44
low 50 0/5
CD24
+/ALDH1
-/CD44
low 25 0/5
CD24
+/ALDH1
-/CD44
low 10 0/5
TNBC-derived:
CD24
+/ALDH1
+/CD44
high 500 5/5
CD24
+/ALDH1
+/CD44
high 100 5/5
CD24
+/ALDH1
+/CD44
high 50 5/5
CD24
+/ALDH1
+/CD44
high 25 5/5
CD24
+/ALDH1
+/CD44
high 10 4/5
TNBC-derived:
CD24
+/ALDH1
-/CD44
low 500 1/5
CD24
+/ALDH1
-/CD44
low 100 0/5
CD24
+/ALDH1
-/CD44
low 50 0/5
CD24
+/ALDH1
-/CD44
low 25 0/5
CD24
+/ALDH1
-/CD44
low 10 0/5
1Tumor cells derived from TPBC or TNBC cells were stably transfected with
eGFP using the lentivirus transduction technique as described in detail in the
Methods section
2Twenty-one days post tumor cell transplantation into the mammary pad of
naïve female BALB/c mice, animals were scarified and eGFP signal from the
tumors were measured using the Maestro™ in vivo imaging system (CRI), and
spectral unmixing was performed to segregate skin and hair auto
fluorescence and to measure the true eGFP signal, as described in detail in
the Methods section. Data is the fraction of mice with tumors (n = 5)
Table 2 Confidence interval (95%) for repopulating
mammary cell frequency
Cell type Confidence intervals for 1/(TICs
frequency)
1
Lower Estimate Upper
TPBC-derived:
CD24
+/ALDH1
+/CD44
high 51.0 27.02 14.4
CD24
+/ALDH1
-/CD44
low 22124.7 3168.93 454.3
TNBC-derived:
CD24
+/ALDH1
+/CD44
high 14.9 6.22 2.8
CD24
+/ALDH1
-/CD44
low 22124.7 3168.93 454.3
1Confidence interval (95%) for repopulating mammary cell frequency for the
data in Table 1. Data were generated using ELDA, a software application for
limiting dilution analysis (LDA) as previously described [34]
Figure 3 CD24
+/ALDH1
+/CD44
high identifies a population of TICs
in both TNBC and TPBC cell fractions. The log-fraction plot of the
limiting dilution model has been generated using ELDA software for
limiting dilution analysis (LDA) after fitting the data from Table 1. The
slopes for CD24
+/ALDH1
+/CD44
high cells derived from TNBC (green
line), CD24
+/ALDH1
-/CD44
low cells derived from TNBC (blue line), CD24
+/ALDH1
+/CD44
high cells derived from TPBC (black line), CD24
+/ALDH1
-/CD44
low cells derived from TPBC (red line), is the log-active
cell fraction. The dotted lines give the 95% confidence interval.
Figure 4 TNBC-TICs proliferate significantly faster than TNBC,
TPBC-TICs, TPBC or parental 4T1 cells. TNBC-TICs (filled circles), TNBC
(open circles), TPBC-TICs (filled squares), TPBC (open squares), or parental
4T1 cells (filled triangles) were seeded at 10
4 cells into T-250 tissue
c u l t u r ef l a s k so nd a y0i nm e d i ac o n t a i n i n gD M E Ms u p p l e m e n t e dw i t h
10% FBS. At various times cell count was determined using a
hemocytometer under a phase-contrast light microscope. Data
represent the mean number of cells ± SD and is the sum of four
independently performed experiments performed in quadruplicates.
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that CD24
+/ALDH1
+/CD44
high cells have a significantly
greater tumor initiating ability than CD24
+/ALDH1
-/
CD44
low cells (Tables 1 and 2). In addition, 95% confi-
dence intervals for repopulating mammary cells frequen-
cies clearly demonstrated that CD24
+/ALDH1
+/CD44
high
cells derived from TNBC and TPBC have a greater
repopulating ability than CD24
+/ALDH1
-/CD44
low cells
derived from TNBC and TPBC (Table 2), and is con-
firmed by log-fraction plot of the limiting dilution
model has been generated using ELDA software (Figure
3). Interestingly, CD24
+/ALDH1
+/CD44
high cells derived
from TNBC (TNBC-TICs) were approximately 4-fold
more efficient than CD24
+/ALDH1
+/CD44
high cells
derived from TPBC (TPBC-TICs) (Table 2). The exact
reason for this difference is currently under investigation
in our laboratory (Kaur et al., in preparation). However,
the data showing that TNBC-TICs exhibit classical signs
of aggressive phenotype shown by human TNBC includ-
ing increased tumor growth (Figure 5) and enhanced
metastatic potential (Figure 6), led us to hypothesize
that the differential expression of mouse HspB1 and
Hsp72/HspA1A, might be a possible explanation (Figure
7). We demonstrated that TNBC-TICs express signifi-
cantly higher levels of mouse HspB1 and Hsp72/
HspA1A than TNBC, TPBC, TPBC-TICs or parental
4T1 cells (Figure 7). This data is in agreement with pre-
vious findings that elevated levels of mouse and human
HspB1 promotes the progression of tumor to more
malignant phenotypes [16,24,25,37], and that elevated
human HspB1 expression in tumors correlated with
shorter disease free survival and recurrence in node-
negative breast cancer [21,22]. Our previous studies
demonstrated that selection of 4T1 cells based on the
expression of mouse HspB1 selects a particular pheno-
type with increased metastatic potential [25]. Further
studies have demonstrated that increased metastatic
potential of 4T1 cells expressing high levels of mouse
HspB1 can be abrogated by suppressing the expression
of mouse HspB1 using small interfering RNA (siRNA)
directed against the mouse hspb1 gene [24]. Nagaraja et
al. recently reported that tumors with high levels of
HspB1 are able to evade the immune system and rapidly
Figure 5 Tumors from TNBC-TICs grow significantly larger than
TNBC, TPBC-TICs, TPBC or parental 4T1 cells. Implantation of
TNBC-TICs into female BALB/c mice resulted in larger tumors than
TNBC, TPBC-TICs, TPBC or parental 4T1 cells. TNBC-TICs (filled circles),
TNBC (open circles), TPBC-TICs (filled squares), TPBC (open squares),
or parental 4T1 cells (filled triangles) 10
4 cells were implanted into
the left breast pad of female BALB/c mice (6-8 weeks old) and
tumor growth was measured using an electronic calipher. Data are
mean tumor volume mm
3 ± SD and are the sum of three
independently performed experiments with five mice per group.
Figure 6 TNBC-TICs produce significantly more metastatic foci
than TNBC, TPBC-TICs, TPBC or parental 4T1 cells. Female BALB/
c mice (6-8 weeks old) were injected with 10
4 parental 4T1 cells
(4T1wt), triangles), TPBC, TPBC-TICs, TNBC or TNBC-TICs into the left
breast pad. Twenty-one days post tumor cell implantation animals
were euthanized and lungs filled with a solution of India Ink (1:6 in
PBS) via intratracheal route. Bars represent the mean number of
lung metastatic foci (10
2 × SEM) and are the sum of three
independently performed experiments with five mice per group. *p
< 0.001 vs parental 4T1 cells (4T1wt).
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Page 9 of 12metastasize, in part, due to HspB1 acting as a repressor
of proteasome function, which in turn results in insuffi-
cient presentation of tumor-associated antigens on the
surface of tumors and a lack of recognition by CD8
+
cytotoxic T lymphocytes (CTL) [36]. These authors
demonstrated that short term silencing of HspB1 using
siRNA or permanent silencing using lentivirus-RNAi
technology enhanced proteasome activity, abrogated
metastatic potential, induced the regression of estab-
lished breast tumors by tumor-specific CD8
+ T cells and
stimulated long-lasting memory responses [36].
Our study suggests that CD24
+/ALDH1
+/CD44
high
identifies TICs in both TNBC and TPBC cell fractions,
TNBC-TICs and TPBC-TICs respectively. These cells
clearly exhibit ability to aggressively repopulate the
mammary tissue of mice in limiting dilution transplanta-
tion assays (Tables 1, 2 and Figure 3). The expression of
aldehyde dehydrogenase 1 (ALDH1) a marker associated
with cancer stem cell-like or TICs features, was signifi-
cantly more common in ER
- tumors. ALDH1
+ cells
were the least frequent in luminal A and B tumors com-
pared to basal-like and HER2
+ subtypes, correlating with
a recent study in breast cancer cell lines [38]. CD44
+/CD24
- cells and ALDH1
+ cells were more frequently
f o u n di nt h eb a s a l - l i k et h a ni nl u m i n a ls u b t y p e s ,h o w -
ever, CD44
+/CD24
- cells but not ALDH1
+ cells were
l e s sc o m m o ni nH E R 2
+ than in basal-like cases. In nor-
mal breast tissue, CD44
+/CD24
- cells were limited to
the basal layer whereas ALDH1
+ cells were found in
both basal and luminal compartments suggesting that
ALDH might be a marker of both bipotential mammary
epithelial stem cells and luminal lineage committed pro-
genitors. The difference in the relative frequency of
CD44
+/CD24
- and ALDH1
+ cells between basal-like and
HER2
+ tumor subtypes may reflect their distinct cell-of-
origin or the alteration of stem cell-like gene expression
programs due to tumor subtype-specific transforming
events [39]. All markers identifying cancer stem cells are
surface markers such as epithelial cell adhesion mole-
cule (EpCAM), CD44, CD24, CD133 and C-X-C chemo-
kine receptor type 4 (CXCR4) definitely expressed on
the normal stem cells at the same time and apparently
changing during cancer stem cell development. Rasheed
et al. reported that ALDH could potentially be an endo-
genous marker for pancreatic TICs after experiments
demonstrated significant clonogenic growth potential
and migratory properties in vitro and in vivo [40]. In
addition, these authors detected 90/269 ALDH
+ tumors
in primary surgical specimens, and verified that their
presence was associated with worse survival [40].
Previous studies clearly demonstrated that the high
expression of human HspB1 in tumors correlates with
increased tumor growth and enhanced metastatic poten-
tial [41]. In addition, the high surface expression of
mouse HspB1 on 4T1 tumors significantly increases their
ability to grow within the abdominal breast gland and to
successfully metastasize and colonize the lungs and the
interaction between host effector cells and tumors
expressing high levels of surface-bound HspB1 results in
abrogation and/or deactivation of host anti-tumor
responses [25,37,41-43]. The rational for this study is
that triple-negative breast cancer (TNBC) is as a type of
breast cancer that has been described to be more aggres-
sive than other kinds of breast cancer [4,44-48]. We
hypothesized that a possible mechanism by which TNBC
exhibit increased aggression and resistance to che-
motherapy as compared to other cancers is, in part, due
to the high expression of mouse and human HspB1.
Conclusions
In conclusion, these studies suggest that these cell lines
could provide an important preclinical model for the
characterization and effective targeting of cancer stem
cells or TICs, and to help further our understanding of
the aggressive nature of TNBC found in humans. This is
significant because TNBC although slightly responsive
to chemotherapy are significantly more difficult to treat
and generally insensitive to most available hormonal or
targeted therapeutic agents than other kinds of breast
cancer. The cell lines described in this study will allow
for a better understanding of the reason for this aggres-
sive nature and will pave the way for the design of more
effective therapeutics.
Figure 7 TNBC-TICs express higher levels of Hsp25 and Hsp72/
HspA1A than TNBC, TPBC-TICs, TPBC or parental 4T1 cells.
TNBC (10
6) (lane 1), parental 4T1 cells (10
6) (lane 2), TPBC (10
6) (lane
3), TNBC-TICs (10
6) (lane 4) or TPBC-TICs (10
6) (lane 5) were lysed
and the amount of Hsp25 or inducible Hsp72/HspA1A was
determined by Western blot analysis using specific Mab as
described in detail in the Materials and Methods section. b-actin
was used as control for equal loading. The intensity of the bands
were analyzed by densitometry with a video densitometer
(Chemilmager™ 5500; Alpha Innotech, San Leandro, CA) using the
AAB software (American Applied Biology). Data is a representative
experiment from three independently performed experiments with
similar results.
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